Sensei Biotherapeutics, Inc. (SNSE) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 17.82 |
| Open | 15.21 |
| Day High | 16.52 |
| Day Low | 13.76 |
| 52-Week High | 36.76 |
| 52-Week Low | 6.33 |
| Volume | 219,467 |
| Average Volume | 52,333 |
| Market Cap | 18.59M |
| PE | -0.1 |
| EPS | -142.72 |
| Moving Average 50 Days | 21.49 |
| Moving Average 200 Days | 16.71 |
| Change | -3.97 |
Data not available
Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results
GlobeNewswire Inc.
Nov 14, 2025 12:30 PM GMT
BOSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial res
Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value
GlobeNewswire Inc.
Oct 30, 2025 1:00 PM GMT
BOSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that its Boa
Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025
GlobeNewswire Inc.
Oct 17, 2025 12:00 PM GMT
6-month progression-free survival (PFS) of 50% in the higher 15 mg/kg dose cohort compares favorably to historical PD-(L)1 refractory settings –All clinical responses, including a complete response, observed in the higher 15 mg/kg dose cohort –Favora